Regenxbio reports 5-year wet AMD efficacy data for sura-vec gene therapy at ASRS meeting

Reuters2026/07/18 18:55

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Regenxbio reported positive long-term follow-up data for surabgene lomparvovec in wet AMD and diabetic retinopathy, supporting durability from a one-time treatment.
Wet AMD Phase I/IIa cohorts showed stable to improved vision through 5 years, with reduced anti-VEGF injection burden, at doses used in pivotal studies.
Diabetic retinopathy ALTITUDE follow-up showed 55% achieved >2-step DRSS improvement at 2.5 years, with 70% avoiding vision-threatening events.
Topline results from the ATMOSPHERE and ASCENT pivotal wet AMD trials are expected in Q4 2026, a key catalyst for the program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenxbio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607181455PR_NEWS_USPR_____PH07513) on July 18, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Regenxbio reports 5-year wet AMD efficacy data for sura-vec gene therapy at ASRS meeting

You may also like

Crypto prices